In SEQUOIA-HCM, how many prespecified secondary endpoints were there?
What is 10
Low peak to trough variability helps mitigate what risk?
What is overexposure or underexposure
In what year id the AHA/ACC update Guidelines to include CMIs as a recommendation for patients with oHCM who remain symptomatic despite treatment with BB or CCB?
What is 2024
Myqorzo is primarily metabolized by this CYP pathway
What is CYP2C9
Patients enrolled in the SEQUOIA-HCM trial and had the benefit of Myqorzo, experienced a mean change from baseline in peak VO2 volume of how many ml per kg per min?
What is 1.7?
Number of days it takes Myqorzo to reach steady state
What is 17
The estimated percentage with HCM that remain undiagnosed.
What is 60%
Having a wide therapeutic windows expands this
What is safety margin
50% of patients with oHCM wait this many years before getting a correct diagnosis
What is Five
Myqorzo was engineered to have a quick what?
What is onset of action